[Prevention of HLA antibody formation in patients with hemato-oncologic diseases by using leukocyte depleted blood preparations].
OBJECTIVE
To determine the effect of transfusion therapy with leukocyte-depleted platelet concentrates in comparison to transfusion support with standard platelet concentrates on the frequency of HLA alloimmunization in hematologic-oncologic patients.


METHODS
Prospective randomized study.


METHODS
Institute for Transfusion Medicine and Immunohematology at a University Hospital.


METHODS
52 hematologic-oncologic patients randomized in 2 groups.


METHODS
Exclusive substitution with leukocyte-depleted blood components (platelet concentrates and packed red cells, filter group) or with standard platelet concentrates and leukocyte-depleted packed red cells (control group). Determination of the development of HLA antibodies.


RESULTS
27% of the patients in the control group (4 out of 15) developed HLA antibodies in contrast to zero patients (0 out of 22) in the filter group (p < 0.02).


CONCLUSIONS
The results of this comparative clinical study show that the consequent and exclusive support with leukocyte-depleted blood components is an effective approach for prevention of HLA alloimmunization in long-term substituted patients.
Adamzik
I D
ID
Institut für Transfusionsmedizin der Christian-Albrechts-Universität zu Kiel.
Jin
J
J
Sachs
V
V
Thomsen
H
H
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000097:blood / Q000628:therapy*; D001787:Blood Group Incompatibility / Q000097:blood / Q000517:prevention & control*; D005260:Female; D006680:HLA Antigens / Q000097:blood*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D007938:Leukemia / Q000097:blood / Q000628:therapy*; D007958:Leukocyte Count; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D017713:Platelet Transfusion; D011247:Pregnancy; D011446:Prospective Studies; D012307:Risk Factors
D006680:HLA Antigens; D007518:Isoantibodies
Vermeidung der HLA-Antikörperbildung bei Patienten mit hämatoonkologischen Erkrankungen durch Einsatz leukozytendepletierter Blutpräparate.